Compare Cytokinetics Inc (CYTK) vs iShares Gold Trust (IAU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares Gold Trust — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while iShares Gold Trust trades at $82.89. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| CYTK | IAU | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $87.26 | $101.57 |
52-Week Low | $34.31 | $62.49 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
IAU (iShares Gold Trust) trades at $82.76, up 0.3% on the day, with technical indicators showing mixed signals - a bullish moving average trend but overbought RSI levels. The ETF benefits from gold's recent momentum as inflation data aligns with expectations and geopolitical tensions boost safe-haven demand. Recent news highlights gold's strong performance with spot prices reaching $4,438/oz following July CPI data.
The outlook remains positive given gold's defensive characteristics amid economic uncertainty, though overbought technical conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy shifts and dollar strength, while institutional buying and central bank demand provide underlying support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →
